| |
|
|
|
Nymox Pharmaceutical Corporatio
|
|
3.82 -0.05 (-1.29%) |
10/23/2017 4:00pm |
|
Open: |
3.85 |
Pre close: |
3.87 |
Target:
|
4.72
|
|
High: |
3.88 |
Low: |
3.82 |
Resistance:
|
4.05
4.24
|
|
Volume: |
68,586 |
Market Cap: |
200.04M |
Support:
|
3.73
3.10
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
3.89
 |
MACD |
MACD(12,26):
|
0.03 |
|
MA(20): |
3.89 |
Signal(12,26,9): |
0.04 |
|
MA(100): |
3.85 |
Stochastic Oscillator |
%K(14,3):
|
23.53 |
|
MA(250): |
3.61  |
%D(3): |
31.81 |
|
Average Volume(K) |
3-Month: |
9399
|
52-Week |
High:
|
5.10 |
|
10-Days: |
6372 |
Low: |
2.67 |
|
RSI |
RSI(14):
|
45.66 |
Change(%): |
16.1 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.230 |
Return on Equity (ttm) |
0.0 |
Shares Out. (M) |
52.00 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-809.8 |
Shares Float (M) |
30.05 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
41.02 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
-93.7 |
% Held by Institutions |
5.88 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
3410 |
|
Book Value (p.s.) |
-0.010 |
EBITDA (p.s.) |
-0.215 |
P/E |
-16.61 |
|
Sales Per Share |
0.003 |
Qtrly Earnings Growth |
0.00 |
P/BV |
-382.00 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-4.68 |
P/S |
1102.42 |
|
Operating Margin |
-6210.79 |
Levered Free Cash Flow
(M) |
-0.44 |
P/CF |
-42.44 |
|
|
|
|
|
|
|
